Jasper Therapeutics (NASDAQ:JSPR) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Jasper Therapeutics (NASDAQ:JSPR) from a sell rating to a hold rating in a report published on Saturday.

A number of other equities research analysts also recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Royal Bank Of Canada set a $3.00 target price on Jasper Therapeutics and gave the stock a “sector perform” rating in a report on Friday, May 15th. Finally, TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $12.00.

Jasper Therapeutics Price Performance

Shares of JSPR opened at $0.69 on Friday. The firm’s 50 day moving average is $0.61 and its 200-day moving average is $1.00. Jasper Therapeutics has a 12-month low of $0.32 and a 12-month high of $3.25. The stock has a market capitalization of $19.28 million, a P/E ratio of -0.21 and a beta of 3.07.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, May 14th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.08. As a group, equities research analysts forecast that Jasper Therapeutics will post -1.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds have recently made changes to their positions in JSPR. Goldman Sachs Group Inc. boosted its position in shares of Jasper Therapeutics by 6,394.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock worth $3,196,000 after buying an additional 1,719,602 shares during the period. Acorn Capital Advisors LLC acquired a new position in Jasper Therapeutics during the third quarter valued at $3,291,000. Velan Capital Investment Management LP raised its position in Jasper Therapeutics by 86.1% during the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock valued at $6,206,000 after buying an additional 1,234,567 shares during the period. Woodline Partners LP purchased a new stake in Jasper Therapeutics in the 3rd quarter worth about $2,475,000. Finally, Millennium Management LLC lifted its stake in Jasper Therapeutics by 194.2% in the 4th quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after acquiring an additional 708,844 shares in the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.